The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payloads with Antibody-Drug Conjugates

2016 ◽  
Vol 128 (28) ◽  
pp. 8080-8083 ◽  
Author(s):  
Robert V. Kolakowski ◽  
Karl T. Haelsig ◽  
Kim K. Emmerton ◽  
Chris I. Leiske ◽  
Jamie B. Miyamoto ◽  
...  
Keyword(s):  
Targeted Delivery ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

scholarly journals Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates

2018 ◽  
Vol 17 (12) ◽  
pp. 2633-2642 ◽  
Author(s):  
Christopher S. Neumann ◽  
Kathleen C. Olivas ◽  
Martha E. Anderson ◽  
Julia H. Cochran ◽  
Steven Jin ◽  
...  
Keyword(s):  
Targeted Delivery ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

Abstract 930: Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates

2018 ◽  
Author(s):  
Christopher S. Neumann ◽  
Kathleen C. Olivas ◽  
Andrew B. Waight ◽  
David Meyer ◽  
Luke V. Loftus ◽  
...  
Keyword(s):  
Targeted Delivery ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

scholarly journals Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates

Antibodies ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 15
Author(s):  
J. Edward Fisher
Keyword(s):  
Targeted Delivery ◽  
Safety Assessment ◽  
Adverse Reactions ◽  
Complex Molecule ◽  
Safety Evaluation ◽  
Clinical Development ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Important Approach ◽  
Antibody Drug

The targeted delivery of drugs by means of linking them to antibodies (Abs) to form antibody–drug conjugates (ADCs) has become an important approach in oncology and could potentially be used in other therapeutic areas. Targeted therapy is aimed at improving clinical efficacy while minimizing adverse reactions. The nonclinical safety assessment of ADCs presents several unique challenges involving the need to examine a complex molecule, each component of which can contribute to the effects observed, in appropriate animal models. Some considerations for the nonclinical safety evaluation of ADCs based on a literature review of ADCs in clinical development (currently or previously) are discussed.

scholarly journals Antibody-Drug Conjugates Used in Breast Cancers

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Aram J. Abbas ◽  
Marah F. Ibrahim ◽  
Maher S. Saifo
Keyword(s):  
Breast Cancer ◽  
Targeted Delivery ◽  
Cytotoxic Drugs ◽  
Breast Cancers ◽  
Receptor Targeting ◽  
Broad Application ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

The prognosis of breast cancer has radically changed in recent years and continues to improve due to the broad application of effective therapies. New targeting strategies including targeted delivery of cytotoxic drugs via receptor-targeting agents have been developed. We summarize recent publications and developments of novel antibody-drug conjugates (ADCs) used to control breast cancer.

A novel self-assembled pH-sensitive targeted nanoparticle platform based on antibody–4arm-polyethylene glycol–pterostilbene conjugates for co-delivery of anticancer drugs

2018 ◽  
Vol 6 (4) ◽  
pp. 656-665 ◽  
Author(s):  
Ke-Feng Liu ◽  
Yan-Xue Liu ◽  
Lin Dai ◽  
Chun-Xiao Li ◽  
Luying Wang ◽  
...  
Keyword(s):  
Polyethylene Glycol ◽  
Cancer Immunotherapy ◽  
Anticancer Drugs ◽  
Targeted Delivery ◽  
Ph Sensitive ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Self Assembled ◽  
Antibody Drug

Recently, antibody–drug conjugates (ADC) have shown potential for cancer immunotherapy by tumor-targeted delivery of anticancer drugs.

The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payloads with Antibody-Drug Conjugates

2016 ◽  
Vol 55 (28) ◽  
pp. 7948-7951 ◽  
Author(s):  
Robert V. Kolakowski ◽  
Karl T. Haelsig ◽  
Kim K. Emmerton ◽  
Chris I. Leiske ◽  
Jamie B. Miyamoto ◽  
...  
Keyword(s):  
Targeted Delivery ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

ASCO-GU 2019: Metastasierte Urothelkarzinome

2019 ◽  
Vol 10 (03) ◽  
pp. 140-141
Author(s):  
Alexander Kretzschmar
Keyword(s):  
San Francisco ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Chapel Hill ◽  
Antibody Drug

Die Therapielandschaft des metastasierten Urothelkarzinoms hat sich seit der Zulassung der ersten Immun-Checkpoint-Inhibitoren verändert. Die neuen Therapien sind deutlich effektiver, allerdings erreichen die Responseraten der neuen Therapien nur bis zu etwa 30 %, beklagte Prof. Matthew Milowsky, Chapel Hill/USA, auf einer Oral Abstract Session auf dem ASCO-GU. In San Francisco gaben erste Vorträge und Poster bereits einen Einblick, wovon diejenigen Patienten profitieren könnten, die auf die etablierten Chemotherapien und die neuen Immuntherapien nicht ansprechen. Manche Onkologen sprechen bereits von der „Post-Checkpoint-Ära”. Als Kandidaten werden vor allem Antikörper-Wirkstoff-Konjugate (antibody-drug conjugates; ADC) gehandelt – und zwar nicht nur zur Therapie des metastasierten Blasenkarzinoms.

Sign in / Sign up

Export Citation Format

Share Document